RNA-sequencing analysis of HepG2 cells treated with atorvastatin

PLoS One. 2014 Aug 25;9(8):e105836. doi: 10.1371/journal.pone.0105836. eCollection 2014.

Abstract

The cholesterol-lowering drug atorvastatin is among the most prescribed drug in the world. Alternative splicing in a number of genes has been reported to be associated with variable statin response. RNA-seq has proven to be a powerful technique for genome-wide splice variant analysis. In the present study, we sought to investigate atorvastatin responsive splice variants in HepG2 cells using RNA-seq analysis to identify novel candidate genes implicated in cholesterol homeostasis and in the statin response. HepG2 cells were treated with 10 µM atorvastatin for 24 hours. RNA-seq and exon array analyses were performed. The validation of selected genes was performed using Taqman gene expression assays. RNA-seq analysis identified 121 genes and 98 specific splice variants, of which four were minor splice variants to be differentially expressed, 11 were genes with potential changes in their splicing patterns (SYCP3, ZNF195, ZNF674, MYD88, WHSC1, KIF16B, ZNF92, AGER, FCHO1, SLC6A12 and AKAP9), and one was a gene (RAP1GAP) with differential promoter usage. The IL21R transcript was detected to be differentially expressed via RNA-seq and RT-qPCR, but not in the exon array. In conclusion, several novel candidate genes that are affected by atorvastatin treatment were identified in this study. Further studies are needed to determine the biological significance of the atorvastatin responsive splice variants that have been uniquely identified using RNA-seq.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Anticholesteremic Agents / pharmacology*
  • Atorvastatin
  • Exons
  • Gene Expression / drug effects*
  • Hep G2 Cells
  • Hepatocytes / drug effects*
  • Hepatocytes / metabolism
  • Heptanoic Acids / pharmacology*
  • Humans
  • Pyrroles / pharmacology*
  • RNA Splicing
  • Sequence Analysis, RNA
  • Transcriptome

Substances

  • Anticholesteremic Agents
  • Heptanoic Acids
  • Pyrroles
  • Atorvastatin

Grant support

This work was funded by the Division of Diagnostics and Intervention, Oslo University Hospital, Norway and by grants from The Blix Family Foundation and Sigrid Wolmar Fund for Heart and Lung Diseases. The sequencing service was provided by the Norwegian Sequencing Centre (www.sequencing.uio.no) a national technology platform supported by the Research Council of Norway and the Southeastern Regional Health Authorities. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.